ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues-Reference-Cited by-同舟云学术

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Published:2017 Issue:3 Volume:105 Page:295-309
ISSN:0028-3835
Container-title:Neuroendocrinology
language:en
Short-container-title:Neuroendocrinology

Author:

Hicks Rodney J.^ORCID,Kwekkeboom Dik J.,Krenning Eric,Bodei Lisa,Grozinsky-Glasberg Simona,Arnold Rudolf,Borbath Ivan,Cwikla Jaroslaw,Toumpanakis Christos,Kaltsas Greg,Davies Philippa,Hörsch Dieter,Tiensuu Janson Eva,Ramage John,

Publisher

S. Karger AG

Subject

Cellular and Molecular Neuroscience,Endocrine and Autonomic Systems,Endocrinology,Endocrinology, Diabetes and Metabolism

Reference83 articles.

1. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K; RAD001 in Advanced Neuroendocrine Tumors Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.

2. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513.

3. Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Oberg K; Vienna Consensus Conference participants: ENETS Consensus Guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016;103:172-185.

4. Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, Oei HY, de Jong M, Visser TJ, Reijs AE, et al: Radiotherapy with a radiolabeled somatostatin analogue, [¹¹¹In-DTPA-D-Phe1]-octreotide. A case history. Ann NY Acad Sci 1994;733:496-506.

5. Krenning EP, Kooij PP, Pauwels S, Breeman WA, Postema PT, De Herder WW, Valkema R, Kwekkeboom DJ: Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996;57(suppl 1):57-61.

Cited by 251 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: an overview of pathophysiology, risk factors, recognition, and treatment;EJNMMI Reports;2024-09-13

2. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-05

3. Cylindrical TGR as early radiological predictor of RLT progression in GEPNETs: a proof of concept;Scientific Reports;2024-07-09

4. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives;Seminars in Nuclear Medicine;2024-07

5. Mid-Treatment Response to 177-Lutetium Dotatate Predicts Overall Outcome in Patients With Advanced Neuroendocrine Tumors;JCO Oncology Practice;2024-06-27